Related Experiment Video
Updated: Mar 6, 2026

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
Published on: April 17, 2017
Labour force participation among individuals with hepatitis C in the US
Philip Jacobs1, Ying Chu Ng, Tania Stafinski
1Department of Public Health Sciences, University of Alberta and Institute of Health Economics, #1200-10405 Jasper Avenue, Edmonton, Alberta T5J 3N4, Canada. philip.jacobs@ualberta.ca
Background:
In 1996, the number of persons newly infected with hepatitis C virus (HCV) in the US was estimated to be 36 000. As a chronic disease that primarily affects younger persons, hepatitis C has the potential to influence employment considerably.
Objective:
To estimate employment effects associated with hepatitis C morbidity.
Design:
An economic model of labour supply, which used the outcome measure workforce participation (yes/no), was applied.
Study Participants:
The study samples (by gender) were comprised of persons 18-65 years of age, with and without serological evidence of HCV infection, and with normal or elevated levels of alanine aminotransferase (ALT) who participated in the National Health and Nutrition Examination Survey III from 1988-1994.
Results:
After controlling for the potential confounding effects of demographic, social, and economic factors, positive HCV status/normal ALT level in males was associated with a 10.7% reduction in labour force participation (when compared with negative HCV status). Positive HCV status and elevated ALT levels was associated with a 17.5% reduction in employment. The results for females were not statistically significant.
Conclusions:
Nationally, the employment response for HCV-positive status and elevated ALT levels translates into an excess non-employment of 48 000 males annually.
More Related Videos
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
11:28Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Drug Excretion: Influencing Factors